Heeding the recommendation of an independent data monitoring committee, Calcimedica Inc. said it is discontinuing the phase II study testing calcium release-activated calcium channel inhibitor Auxora ...

CalciMedica has terminated a Phase II study on its lead asset, Auxora (zegocractin), in acute kidney injury (AKI) with ...

According to the company, the committee said that the safety concerns warrant reevaluation of the study design, particularly ...

CalciMedica shares fell after the company stopped its Phase 2 KOURAGE trial for Auxora due to safety concerns.

CalciMedica shares were 82% lower, at 91 cents, after the company said it was discontinuing its Phase 2 clinical trial evaluating Auxora in patients with Stage 2 or Stage 3 acute kidney injury with ...

Immune checkpoint inhibitor (ICI) pneumonitis is a potentially life-threatening immune-related adverse event associated with ICI therapy across various malignancies. ICIs enhance antitumour immunity ...

Safety concern warrants reevaluation of study design, including enrollment criteria Potential future trial with Auxora in AKI to be evaluated after data analysis LA ...

CalciMedica had been evaluating the therapy, called Auxora, in the Kourage trial of patients with stage 2 or 3 AKI with ...

CalciMedica Inc. ("CalciMedica" or the "Company") , a clinical-stage biopharmaceutical company developing novel calcium ...

Investing.com -- CalciMedica Inc. (NASDAQ:CALC) stock plunged 80% Wednesday after the company announced it was discontinuing its Phase 2 KOURAGE clinical trial for acute kidney injury following safety ...

Two recent deaths at Chicago-area nursing homes highlight problem of poor care, difficulty in holding those responsible accountable, advocates say.

Background High-flow nasal cannula (HFNC) therapy is increasingly used for lower respiratory tract infections (LRTIs) in infants and young children, but recommendations vary, and standardised practice ...